Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2008

View Archived Issues

Preclinical data on nucleoside polymerase inhibitors IDX-102, IDX-184 presented

Results from ASSIST-2 show efficacy of iclaprim in cSSSI

Met inhibitor JNJ-38877605 advanced to clinical evaluation for metastasized malignancies

SK inhibitor shows good pharmacokinetics and antitumor activity in preclinical studies

Novel Hsp90 inhibitor shows benefits in breast cancer models in vivo

Protherics reports results from phase IIb DEEP study of GSK's Digibind in preeclampsia

Agennix initiates phase II study of oral talactoferrin for severe sepsis

Amkor completes its phase I study of NEU-2000 in brain injury

FDA accepted Addrenex's NDA for CloniBID to treat hypertension

Spectrum reports positive results from phase IIb study of LHRH antagonist ozarelix in BPH

GSK to acquire Sirtris Pharmaceuticals for approximately USD 720 million

Cytheris initiates phase I clinical trial of CYT-107 in immunodeficient transplant recipients

MacroChem acquires Virium Pharmaceuticals

Alizyme reports negative results from phase III clinical trial of renzapride in IBS-C

Clinuvel announces results from its phase I studies of CUV-1647

PTC Therapeutics initiates phase IIb clinical trial of PTC-124 in DMD/BMD

European CHMP issues positive opinion for conditional approval of Tyverb

Volibris approved in E.U. for functional class II and III PAH

ACR-16 begins phase III for Huntington's disease

CHMP issues positive opinion for icatibant in HAE; FDA issues not approvable letter

CHMP issues positive opinions for two Merck medicines

Ligand initiates phase II LGD-4665 trial in idiopathic thrombocytopenic purpura

European Commission approves Viread for chronic hepatitis B

Schering-Plough/Merck receives not-approvable letter from FDA

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

Data from ranibizumab AMD studies presented at the ARVO meeting

Recent Lilly and GSK patents describe new anxiolytic and antidepressant agents

Micellar formulation of calcineurin inhibitor voclosporin effective and well-tolerated in dry eye

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...